Alimentary Health Extends Probiotic Development Collaboration with P&G providing Alimentary Health with worldwide commercialisation rights to prescription and medical food products
Alimentary Health Limited today announces an extension to its collaborative relationship with long-term partner, the Procter & Gamble Company (NYSE:PG), aimed at researching the “next generation” of probiotic organisms. By extending the collaboration agreement, Alimentary Health and P&G will further their joint research into the next generation of probiotic organisms, focusing on human disease or conditions related to inflammation and gastrointestinal disorders. Significantly, under the terms of the new agreement, P&G has worldwide commercialisation rights for OTC products while Alimentary Health has worldwide commercial rights for medical prescription and medical food products. Alimentary Health and P&G first partnered in 1999, before entering a collaborative agreement in 2006 as part of P&G’s open innovation program, Connect and Develop. The collaboration has resulted in the identification of probiotic organisms that display medical efficacy in combating gastrointestinal disorders. Specifically, the research lead to the co-development of P&G’s Align® Probiotic, a daily OTC supplement recommended to help build and maintain a healthy digestive system and support natural digestive balance. Align, which contains Alimentary Health’s patented probiotic Bifantis (Bifidobacterium infantis 35624), is sold across the United States with plans to launch in Canada in H2 2012. It is the most recommended probiotic by gastroenterologists in the US. The co-development and successful launch of Align has provided commercial validation for Alimentary Health’s probiotic bacteria research programme and demonstrated the market potential for clinically proven probiotic products. Barry Kiely, Alimentary Health CEO, said: “We are pleased to announce the expansion and further strengthening of our relationship with P&G. The science based approach of both companies has laid a considerable foundation for the development of further products from this exciting group of microorganisms, which includes BifantisR (B. infantis 35624). We are excited about the strategic direction this agreement outlines for Alimentary Health: the delineation of the probiotic market into OTC products and medical foods & prescription medicines establishes a strategy for Alimentary Health to bring new treatments to the market.” “We’re delighted to extend our agreement with Alimentary Health”, said Lisa Ernst, R&D Manager, P&G Personal Health Care “Since nationally launching Align® in the US in March 2009, consumers have benefited from the strong science behind the brand. Now, we look forward to additional research in this area to further meet our consumers’ needs in managing their gastrointestinal health.”
About Alimentary Health Ltd (AH)
AH is a specialty biotechnology company which is focused on the discovery, development and commercialisation of proprietary probiotic and pharmabiotic treatments for gastro-intestinal disorders and other inflammatory conditions. AH is the foundation industry partner of the Alimentary Pharmabiotic Centre based at University College Cork, Ireland.
About Procter & Gamble (NYSE:PG)
Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Pampers®, Tide®, Ariel®, Always®, Whisper®, Pantene®, Mach3®, Bounty®, Dawn®, Pringles®, Charmin®, Downy®, Lenor®, Iams®, Crest®, Oral-B®, Actonel®, Duracell®, Olay®, Head & Shoulders®, Wella®, Gillette®, and Braun®. The P&G community consists of almost 140,000 employees working in over 80 countries worldwide. Please visit www.pg.com for the latest news and in-depth information about P&G and its brands.